普拉克索联合美多巴治疗帕金森病的效果及其对血尿酸、炎症因子的影响

Curative effect of pramipexole combined with madopar on Parkinson’s disease and the influence on blood uric acid and inflammatory factors

目的 探讨普拉克索联合美多巴治疗帕金森病的疗效及对患者血尿酸、炎症因子的影响。方法 抽取河南科技大学第一附属医院2015年10月至2017年10月收治的帕金森病患者120例,按随机抽签分为观察组(n=60)和对照组(n=60),对照组采用美多巴治疗,观察组在对照组基础上加用普拉克索治疗,均治疗3个月,比较两组临床疗效及治疗前后帕金森病评价量表(UPDRS)评分、生活质量量表(QOL-2)评分,血尿酸及炎症因子水平变化,以及不良反应发生率。结果 观察组治疗总有效率为95.00%,高于对照组(80.00%,P<0.05);治疗后两组肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及白细胞介素-1β(IL-1β)均降低,且观察组低于对照组(P<0.05);治疗后对照组血尿酸水平较治疗前降低,且低于观察组(P<0.05),而观察组尿酸虽较治疗前降低,但差异未见统计学意义(P>0.05);治疗后两组QOL-2各维度评分均升高,UPDRS评分降低,且观察组QOL-2各维度评分高于对照组,UPDRS评分低于对照组(P<0.05);观察组不良反应发生率低于对照组(P<0.05)。结论 普拉克索联合美多巴治疗帕金森病能提高患者临床疗效,降低炎症因子水平,并能抑制尿酸下降程度,缓解病情,提高生活质量,且能减少不良反应。

Objective To investigate the curative effect of pramipexole combined with madopar in the treatment of Parkinson’s disease and the influence on blood uric acid and inflammatory factors of patients.Methods A total of 120 patients with Parkinson’s disease who were admitted to the First Affiliated Hospital of Henan University of Science and Technology from October 2015 to October 2017 were randomly divided into the observation group(n=60)and the control group(n=60).The control group was treated with madopar,while the observation group was treated with pramipexole combined with madopar.The clinical curative effect after 3 months of treatment,scores of the the unified Parkinson’s disease rating scale(UPDRS)and the quality of life scale(QOL-2)before and after treatment,changes in levels of blood uric acid and inflammatory factors before and after treatment,and the incidence of adverse reactions were compared between the two groups.Results The total response rate of the observation group was significantly higher than that of the control group(95.00%vs.80.00%),P<0.05.Levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and(IL-1β)in the observation group were significantly decreased after treatment,and they were significantly lower than those in the control group(P<0.05).The blood uric acid level in the control group was significantly decreased after treatment,and it was significantly lower than that in the observation group(P<0.05).Although the uric acid level in the observation group was decreased after treatment,the difference was not statistically significant(P>0.05).Scores of QOL-2 of each group were significantly increased,while scores of UPDRS were significantly decreased after treatment.Scores of QOL-2 of the observation group were significantly higher than those of the control group,while scores of UPDRS were significantly lower than those of the control group(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusions Pramexole combined with Madopar in the treatment of Parkinson’s disease can significantly improve the clinical curative effect,reduce the levels of inflammatory factors,inhibit the degree of uric acid decline,relieve the disease,improve quality of life,and reduce adverse reactions.